What can we learn from the molecular classification of Glioblastoma (GBM)?

Sally Church on Pharma Strategy Blog continues her series of posts looking in more detail at Glioblastoma (GBM), the most common brain cancer.

Both brainstem gliomas and glioblastomas have poor prognosis, which raises the importance of translational medical research that could lead to new targeted therapies.

Research by Phillips et al, has shown that Akt and Notch signaling are hallmarks of poor prognosis, suggesting that identification of molecular subtypes may be useful in the development of new therapies.

Following on from the recent AACR special conference on targeting PI3K/mTOR signaling in cancer, Sally discusses in her blog post, the consequences that may follow from targeting the Akt pathway.


, , , , , , , , , , ,

error: Content is protected !!